XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections

Abstract

The contribution of cross-presenting XCR1+ dendritic cells (DCs) and SIRPα+ DCs in maintaining T cell function during exhaustion and immunotherapeutic interventions of chronic infections remains poorly characterized. Using the mouse model of chronic LCMV infection, we found that XCR1+ DCs are more resistant to infection and highly activated compared with SIRPα+ DCs. Exploiting XCR1+ DCs via Flt3L-mediated expansion or XCR1-targeted vaccination notably reinvigorates CD8+ T cells and improves virus control. Upon PD-L1 blockade, XCR1+ DCs are not required for the proliferative burst of progenitor exhausted CD8+ T (T_PEX) cells but are indispensable to sustain the functionality of exhausted CD8+ T (T_EX) cells. Combining anti-PD-L1 therapy with increased frequency of XCR1+ DCs improves functionality of T_PEX and T_EX subsets, while increase of SIRPα+ DCs dampened their proliferation. Together, this demonstrates that XCR1+ DCs are crucial for the success of checkpoint inhibitor-based therapies through differential activation of exhausted CD8+ T cell subsets.

Keywords: CP: Immunology; Flt3L; LCMV; SIRPɑ+ DCs; T cell exhaustion; XCR1+ DCs; anti-PD-L1; chronic infection; immunotherapy; therapeutic vaccination.